In a report released today, Steven Halper from Cantor Fitzgerald reiterated a Hold rating on CPSI (CPSI), with a price target of $32. The company’s shares opened today at $30.
“. We reiterate our Neutral rating on CPSI shares while increasing our price target to $32 from $28. Before the open on Friday, February 15, CPSI reported 4Q18 results. Adjusted EPS were above FactSet consensus and our estimates. Bookings grew 26% sequentially, which is encouraging. TruBridge bookings were solid as well. The company did not provide specific 2019 financial guidance, but management believes continued Trubridge execution should drive top- line growth and its cost savings initiative ($10M bottom-line benefit) should drive improved profitability. It remains to be seen if the company can achieve these goals.”
According to TipRanks.com, Halper is a top 100 analyst with an average return of 19.9% and a 66.1% success rate. Halper covers the Services sector, focusing on stocks such as WellCare Health Plans, Tivity Health Inc, and Evolent Health.
CPSI has an analyst consensus of Hold, with a price target consensus of $30, a 0.0% upside from current levels. In a report released today, Oppenheimer also maintained a Hold rating on the stock.
See today’s analyst top recommended stocks >>
The company has a one-year high of $34.65 and a one-year low of $23.81. Currently, CPSI has an average volume of 121.4K.
Based on the recent corporate insider activity of 39 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Computer Programs & Systems, Inc. engages in the provision of healthcare information technology solutions and services. It operates through the following segments: Acute Care EHR, Post-acute Care EHR, and TruBridge. The Acute EHR segment consists of acute care software solutions and support generated by Evident and Healthand.